Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

MDGL stock hub

Madrigal Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

MDGLis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

11.8B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

MDGL

In the news

Latest news · MDGL

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-49.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-22.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All MDGL market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

203

Groups with data

Currency

USD

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001157601
Company name	Madrigal Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	558868105
Employees	915
Employees Change	387%
Employees Change Percent	73.3
Enterprise value	$11.3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US5588681057
Last refreshed	2026-05-10
Market cap	$11.8B
Market cap category	Large-Cap
Price	$510
Price currency	USD
Rev Per Employee	1,237,693.99x
Sector	Healthcare
Sic	2834
Symbol	MDGL
Website	https://www.madrigalpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.63%
EV Sales Forward	7.02x
EV/Sales	9.97x
FCF yield	-2.32%
P/B ratio	21.63x
P/S ratio	10.38x
PS Forward	7.31x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-27.68%
EBITDA Margin	-27.55%
Gross margin	93.07%
Gross Profit	$1.1B
Gross Profit Growth	243.73%
Gross Profit Growth Q	114.33%
Net Income	$-309.4M
Net Income Growth Years	1%
Pretax Margin	-27.32%
Profit Margin	-27.32%
Profit Per Employee	$-338,183
ROA	-17.62
Roa5y	-42.5
ROCE	-35.26
ROE	-49.35
Roe5y	-101.6
ROIC	-22.77

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	70.74%
Cagr3y	18.51%
Cagr5y	31.36%
EPS Growth Years	1
Revenue Growth	256.82x
Revenue Growth Q	126.84x
Revenue Growth Quarters	4x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.02
Assets	$1.2B
Cash	$812.8M
Current Assets	$1.2B
Current Liabilities	$338.3M
Debt	$347.3M
Debt Equity	$0.64
Equity	$543.5M
Interest Coverage	-11.68
Liabilities	$683.9M
Long Term Assets	$45M
Long Term Liabilities	$345.6M
Net Cash	$465.5M
Net Cash By Market Cap	$3.96
Net Cash Growth	-35.65%
Net Debt Equity	$-0.86
Tangible Book Value	$536.2M
Tangible Book Value Per Share	$23.27
WACC	-1.28

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.5
Inventory Turnover	0.94
Net Working Capital	$33M
Quick ratio	2.96
Working Capital	$844M
Working Capital Turnover	$1.36

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.67%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	70.68%
200-day SMA	474
3Y total return	66.48%
50-day SMA	490.7
50-day SMA vs 200-day SMA	50over200
5Y total return	291.08%
All Time High	615
All Time High Change	-17.07%
All Time High Date	2025-12-24
All Time Low	6.6
All Time Low Change	7,627.88%
All Time Low Date	2016-08-02
ATR	22.74
Beta	-1.04
Beta1y	0.06
Beta2y	0.28
Ch YTD	-12.42
High	541.6
High52	615
High52 Date	2025-12-24
High52ch	-17.07%
Low	510
Low52	265
Low52 Date	2025-05-27
Low52ch	92.47%
Ma50ch	3.94%
Price vs 200-day SMA	7.6%
RSI	48.45
RSI Monthly	60.75
RSI Weekly	56.09
Sharpe ratio	1.32x
Sortino ratio	2.44
Total Return	2.67%
Tr YTD	-12.42
Tr1m	-0.36%
Tr1w	-0.72%
Tr3m	6.79%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	13
Analyst Count Top	4
Analyst Price Target Top	$649
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-4.04
Earnings Revenue Estimate	300,969,792x
Earnings Revenue Estimate Growth	119.29x
Operating Income	$-313.5M
Operating margin	-27.68
Price target	$672
Price Target Change	$31.67
Price Target Change Top	$27.2

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	12,606,538%
Float Percent	54.68%
Net Borrowing	228,336,000
Shares Insiders	8.43%
Shares Institutions	69.89%
Shares Out	23,055,659
Shares Qo Q	27.17%
Shares Yo Y	-2.67%
Short Float	31.83%
Short Ratio	10.46
Short Shares	17.4

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-383.6M
Average Volume	276,484.5x
Bv Per Share	23.59
CAPEX	$-4.3M
Ch1m	-0.36
Ch1w	-0.72
Ch1y	70.68
Ch3m	6.79
Ch3y	66.48
Ch5y	291.1
Ch6m	4.25
Change	-4.64%
Change From Open	-4.67
Close	534.9
Days Gap	0.03
Depreciation Amortization	1,513,000
Dollar Volume	193,456,641.9
Earnings Date	2026-05-06
Earnings Time	bmo
EBIT	$-313.5M
EBITDA	$-312M
EPS	$-13.65
F Score	2
FCF	$-272.4M
FCF EV Yield	-2.41x
FCF Per Share	$-11.82
Financing CF	249,673,000
Fiscal Year End	December
Founded	2,011
Investing CF	60,633,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-19
Ma150	500.4
Ma150ch	1.94%
Ma20	521.7
Ma20ch	-2.23%
Net CF	43,542,000
Next Earnings Date	2026-08-04
Open	535
Optionable	Yes
Position In Range	0.13
Post Close	510
Postmarket Change Percent	0.97
Postmarket Price	$515
Ppne	14,238,000
Price Date	2026-05-08
Ptbv Ratio	21.93
Relative Volume	1.37x
Revenue	1,132,490,000x
SBC By Revenue	9.82x
Share Based Comp	111,217,000
Tr6m	4.25%
Us State	Pennsylvania
Volume	379,297
Z Score	6.61

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does MDGL pay a dividend?

Capital-return profile for this ticker.

Performance

MDGL stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns MDGL?

Insider, institutional, and short-interest positioning.

Institutional ownership

+69.9%

Float: +54.7% of shares outstanding

Insider ownership

+8.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

MDGL momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

48.5

Neutral momentum band

Price vs 200-day MA

+7.6%

50/200-day relationship not available

Beta (5Y)

-1.04

Less volatile than the market

Sharpe ratio

1.32

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About MDGL

Hub-level FAQ points readers to the deeper analysis pages.

What is the current MDGL stock rating?

Madrigal Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full MDGL analysis?

The full report lives at /stocks/MDGL/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for MDGL?

The latest report frames MDGL around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the MDGL page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.